Progression of biological reagent therapy for ankylosing spondylitis

( views:, downloads: )
Author:
GU Jie-ruo()
Journal Title:
JOURNAL OF MODERN CLINICAL MEDICAL BIOENGINEERING
Issue:
Volume 12, Issue 06, 2006
DOI:
Key Word:

Abstract:

  • [1]Gorman J,Sack K,Davis J.Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α.N Engl J Med,2002,346:1349-1356.
  • [2]Braun J,Brandt J,Listing J,et al.Treatment of active ankylosing spondylitis with infliximab:a randomized controlled multicentre trial.Lancet,2002,359:1187-1193.
  • [3]Antoni C,Braun J.Side effects of anti-TNF therapy:Current knowledge.Clin Exp Rheumatol,2002,20:152-157.
  • [4]Brandt J,Haibel H,Reddig J,et al.Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.J Rheumatol,2002,29:118-122.
  • [5]Wolfe F,Michaud K,Anderson J,et al.Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.Arthritis Rheum,2004,50:372-379.
  • [6]Crum NF,Ledeman ER,Wallace MR.Infections associated with tumor necrosis factor-alpha antagonists.Medicine (Baltimore),2005,84:291-302.
  • [7]Goffe B.Etanencept (Enbrel)-an update.Skin Therapy Lett,2004,9:1-9.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn